Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions

Ji Guang Wang; Ma Lourdes Bunyi; Yook Chin Chia; Kazuomi Kario; Takayoshi Ohkubo; Sungha Park; Apichard Sukonthasarn; Jam Chin Tay; Yuda Turana; Narsingh Verma; Tzung Dau Wang; Yutaka Imai

doi:10.1111/jch.14074

Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions

Ji Guang Wang, Ma Lourdes Bunyi, Yook Chin Chia, Kazuomi Kario, Takayoshi Ohkubo, Sungha Park, Apichard Sukonthasarn, Jam Chin Tay, Yuda Turana, Narsingh Verma, Tzung Dau Wang, Yutaka Imai

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Hypertension is one of the most powerful modifiable risk factors for cardiovascular disease. It is usually asymptomatic and therefore essential to measure blood pressure regularly for the detection of hypertension. Home blood pressure monitoring (HBPM) is recognized as a valuable tool to monitor blood pressure and facilitate effective diagnosis of hypertension. It is useful to identify the masked or white-coat hypertension. There is also increasing evidence that supports the role of HBPM in guiding antihypertensive treatment, and improving treatment compliance and hypertension control. In addition, HBPM has also shown prognostic value in predicting cardiovascular events. Despite these benefits, the use of HBPM in many parts of Asia has been reported to be low. An expert panel comprising 12 leading experts from 10 Asian countries/regions convened to share their perspectives on the realities of HBPM. This article provides an expert summary of the current status of HBPM and the key factors hindering its use. It also describes HBPM-related initiatives in the respective countries/regions and presents strategies that could be implemented to better support the use of HBPM in the management of hypertension.

Original language	English
Pages (from-to)	3-11
Number of pages	9
Journal	Journal of Clinical Hypertension
Volume	23
Issue number	1
DOIs	https://doi.org/10.1111/jch.14074
Publication status	Published - 2021 Jan

Bibliographical note

Funding Information:
Jiguang WANG received grants from Bayer, Chengdu DiAo, MSD, and Beijing ShuangHe, and lecture and consulting fees from AstraZeneca, Bayer, Omron Healthcare, Salubris, Servier, and Takeda. Yook Chin CHIA received grants from Pfizer and Omron Healthcare for Young Investigators' Network, and speaker honoraria from Pfizer, Servier, and Omron Healthcare. Kazuomi KARIO received grants and lecture fees from Omron Healthcare. Takayoshi OHKUBO and Jam Chin Tay received grants from Omron Healthcare. Tzung‐Dau WANG received research grants from Novartis and Omron Healthcare, and honoraria for lectures and consultations from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron Healthcare, Pfizer, Sanofi, and Servier. The rest of the authors declare no conflict of interest.

Publisher Copyright:
© 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jch.14074

Cite this

Wang, Ji Guang ; Bunyi, Ma Lourdes ; Chia, Yook Chin ; Kario, Kazuomi ; Ohkubo, Takayoshi ; Park, Sungha ; Sukonthasarn, Apichard ; Tay, Jam Chin ; Turana, Yuda ; Verma, Narsingh ; Wang, Tzung Dau ; Imai, Yutaka. / Insights on home blood pressure monitoring in Asia : Expert perspectives from 10 countries/regions. In: Journal of Clinical Hypertension. 2021 ; Vol. 23, No. 1. pp. 3-11.

@article{3569c20919be4d0e83ed8d3da07ccc03,

title = "Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions",

abstract = "Hypertension is one of the most powerful modifiable risk factors for cardiovascular disease. It is usually asymptomatic and therefore essential to measure blood pressure regularly for the detection of hypertension. Home blood pressure monitoring (HBPM) is recognized as a valuable tool to monitor blood pressure and facilitate effective diagnosis of hypertension. It is useful to identify the masked or white-coat hypertension. There is also increasing evidence that supports the role of HBPM in guiding antihypertensive treatment, and improving treatment compliance and hypertension control. In addition, HBPM has also shown prognostic value in predicting cardiovascular events. Despite these benefits, the use of HBPM in many parts of Asia has been reported to be low. An expert panel comprising 12 leading experts from 10 Asian countries/regions convened to share their perspectives on the realities of HBPM. This article provides an expert summary of the current status of HBPM and the key factors hindering its use. It also describes HBPM-related initiatives in the respective countries/regions and presents strategies that could be implemented to better support the use of HBPM in the management of hypertension.",

author = "Wang, {Ji Guang} and Bunyi, {Ma Lourdes} and Chia, {Yook Chin} and Kazuomi Kario and Takayoshi Ohkubo and Sungha Park and Apichard Sukonthasarn and Tay, {Jam Chin} and Yuda Turana and Narsingh Verma and Wang, {Tzung Dau} and Yutaka Imai",

note = "Funding Information: Jiguang WANG received grants from Bayer, Chengdu DiAo, MSD, and Beijing ShuangHe, and lecture and consulting fees from AstraZeneca, Bayer, Omron Healthcare, Salubris, Servier, and Takeda. Yook Chin CHIA received grants from Pfizer and Omron Healthcare for Young Investigators' Network, and speaker honoraria from Pfizer, Servier, and Omron Healthcare. Kazuomi KARIO received grants and lecture fees from Omron Healthcare. Takayoshi OHKUBO and Jam Chin Tay received grants from Omron Healthcare. Tzung‐Dau WANG received research grants from Novartis and Omron Healthcare, and honoraria for lectures and consultations from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron Healthcare, Pfizer, Sanofi, and Servier. The rest of the authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC",

year = "2021",

month = jan,

doi = "10.1111/jch.14074",

language = "English",

volume = "23",

pages = "3--11",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell",

number = "1",

}

Insights on home blood pressure monitoring in Asia : Expert perspectives from 10 countries/regions. / Wang, Ji Guang; Bunyi, Ma Lourdes; Chia, Yook Chin; Kario, Kazuomi; Ohkubo, Takayoshi; Park, Sungha; Sukonthasarn, Apichard; Tay, Jam Chin; Turana, Yuda; Verma, Narsingh; Wang, Tzung Dau; Imai, Yutaka.

In: Journal of Clinical Hypertension, Vol. 23, No. 1, 01.2021, p. 3-11.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Insights on home blood pressure monitoring in Asia

T2 - Expert perspectives from 10 countries/regions

AU - Wang, Ji Guang

AU - Bunyi, Ma Lourdes

AU - Chia, Yook Chin

AU - Kario, Kazuomi

AU - Ohkubo, Takayoshi

AU - Park, Sungha

AU - Sukonthasarn, Apichard

AU - Tay, Jam Chin

AU - Turana, Yuda

AU - Verma, Narsingh

AU - Wang, Tzung Dau

AU - Imai, Yutaka

N1 - Funding Information: Jiguang WANG received grants from Bayer, Chengdu DiAo, MSD, and Beijing ShuangHe, and lecture and consulting fees from AstraZeneca, Bayer, Omron Healthcare, Salubris, Servier, and Takeda. Yook Chin CHIA received grants from Pfizer and Omron Healthcare for Young Investigators' Network, and speaker honoraria from Pfizer, Servier, and Omron Healthcare. Kazuomi KARIO received grants and lecture fees from Omron Healthcare. Takayoshi OHKUBO and Jam Chin Tay received grants from Omron Healthcare. Tzung‐Dau WANG received research grants from Novartis and Omron Healthcare, and honoraria for lectures and consultations from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, Menarini, Novartis, Omron Healthcare, Pfizer, Sanofi, and Servier. The rest of the authors declare no conflict of interest. Publisher Copyright: © 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC

PY - 2021/1

Y1 - 2021/1

N2 - Hypertension is one of the most powerful modifiable risk factors for cardiovascular disease. It is usually asymptomatic and therefore essential to measure blood pressure regularly for the detection of hypertension. Home blood pressure monitoring (HBPM) is recognized as a valuable tool to monitor blood pressure and facilitate effective diagnosis of hypertension. It is useful to identify the masked or white-coat hypertension. There is also increasing evidence that supports the role of HBPM in guiding antihypertensive treatment, and improving treatment compliance and hypertension control. In addition, HBPM has also shown prognostic value in predicting cardiovascular events. Despite these benefits, the use of HBPM in many parts of Asia has been reported to be low. An expert panel comprising 12 leading experts from 10 Asian countries/regions convened to share their perspectives on the realities of HBPM. This article provides an expert summary of the current status of HBPM and the key factors hindering its use. It also describes HBPM-related initiatives in the respective countries/regions and presents strategies that could be implemented to better support the use of HBPM in the management of hypertension.

AB - Hypertension is one of the most powerful modifiable risk factors for cardiovascular disease. It is usually asymptomatic and therefore essential to measure blood pressure regularly for the detection of hypertension. Home blood pressure monitoring (HBPM) is recognized as a valuable tool to monitor blood pressure and facilitate effective diagnosis of hypertension. It is useful to identify the masked or white-coat hypertension. There is also increasing evidence that supports the role of HBPM in guiding antihypertensive treatment, and improving treatment compliance and hypertension control. In addition, HBPM has also shown prognostic value in predicting cardiovascular events. Despite these benefits, the use of HBPM in many parts of Asia has been reported to be low. An expert panel comprising 12 leading experts from 10 Asian countries/regions convened to share their perspectives on the realities of HBPM. This article provides an expert summary of the current status of HBPM and the key factors hindering its use. It also describes HBPM-related initiatives in the respective countries/regions and presents strategies that could be implemented to better support the use of HBPM in the management of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=85092317766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092317766&partnerID=8YFLogxK

U2 - 10.1111/jch.14074

DO - 10.1111/jch.14074

M3 - Review article

C2 - 33043574

AN - SCOPUS:85092317766

VL - 23

SP - 3

EP - 11

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 1

ER -

Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this